(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Trial Profile

(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Betrixaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms APEX
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 30 Nov 2017 According to a Portola Pharmaceuticals media release, Impact of D-Dimer Assays in the Evaluation of APEX Trial Outcomes will be presented at the 59th American Society of Hematology (ASH) Annual Meeting.
    • 15 Nov 2017 Results of a substudy assessing effect of full dose betrixaban in reducing venous thromboembolism related mortality, presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Results of a substudy assessing the effect of extended-duration betrixaban versus standard-duration enoxaparin on presence and extent of thrombus burden of deep vein thrombosis, presented at the 90th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top